Botanical species · safety record

Anagallis arvensis

The EFSA Compendium of Botanicals holds 6 constituent measurements and 3 adverse-effect records for Anagallis arvensis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Anagallis arvensis L.

6Constituent measurements

3Safety records

6Cited sources

9Licensed products (Canada)

Also recorded as

Lysimachia arvensis (L.) U.Manns & Anderb.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 9 licensed products naming Anagallis arvensis as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Whole plant of the scarlet variety

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Pentacyclic triterpene saponins	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Pentacyclic triterpene saponins	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Alkaloids	Seed	Solvent extraction	2.21 Percent	—	No resolvable identifier
Anagalloside	Live plants	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Saponins	Seed	Solvent extraction	1.29 Percent	—	No resolvable identifier
Tannins	Seed	Solvent extraction	9.56 Percent	—	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Nephrotoxicity	Urogenital: kidneys	Aerial part of plants	—	Cattle (as animal)	Short-term toxicity	Resolve DOI
Nephrotoxicity	Urogenital: kidneys	Aerial part of plants	Fresh	Sheep (as animal)	Case report	No resolvable identifier
Nephrotoxicity	Urogenital: kidneys	Unspecified	Raw, no heat treatment	Cattle (as animal)	Case report	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Rivero, R., Zabala, A., Gianneechini, R., Gil, J., Moraes, J. Anagallis arvensis poisoning in cattle and sheep in Uruguay. Veterinary and human toxicology, 2001, vol. 43, no. 1, p. 27-30.
Harish, B. R., Naik, B. M. Chandra., Somashekar, S. H., Kumar, R. Vijaya., Jayakumar, S. R., Krishnappa, G. Blue pimpernel toxicity in cattle and buffaloes. Indian veterinary journal, 2006, vol. 83, no. 9, p. 947-949.
Roche, M. J., McCowan, C. I., Kelly, J. C. Suspected poisoning of cattle by scarlet pimpernel (Lysimachia arvensis L.) . Australian veterinary journal, 2012, vol. 90, no. 7, p. 269-271. DOI
Abbas, M. N., Rana, S. A., Shahid, M., Rana, N., Mahmood-ul-Hassan, M., Hussain, M. Chemical evaluation of weed seeds mixed with wheat grains at harvest. Journal of animal and plant sciences, 2012, vol. 22, no. 2, p. 283-288.
Soberon, Jose R., Sgariglia, Melina A., Pastoriza, Ana C., Soruco, Estela M., Jager, Sebastian N., Labadie, Guillermo R., Sampietro, Diego A., Vattuone, Marta A. Antifungal activity and cytotoxicity of extracts and triterpenoid saponins obtained from the aerial parts of Anagallis arvensis L. . Journal of ethnopharmacology, 2017, vol. 203, p. 233-240. DOI
Abdel-Gawad, MM., El-Amin, SM., Ohigashi, H., Watanabe, Y., Takeda, N., Sugiyama, H., Kawanaka, M. Molluscicidal saponins from Anagallis arvensis against schistosome intermediate hosts . Japanese journal of infectious diseases, 2000, vol. 53, no. 1, p. 17-19.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature